

Restricted Use/Recipients Only

---

**From:** Moro, Pedro (CDC/NCEZID/DHQP/ISO) <psm9@cdc.gov>  
**Sent:** Thursday, March 21, 2024 12:36 PM  
**To:** Ennulat, Carol (CDC/NCEZID/DHQP/ISO) (CTR) <scq4@cdc.gov>  
**Cc:** Brown, Hannah (CDC/NCEZID/DHQP/ISO) (CTR) <rw12@cdc.gov>  
**Subject:** RE: VAERS 2742477

The patient did not receive the adult RSV vaccine, (b)(6)  
(b)(6) FDA is following up on nirsevimab reports so I would not do anything with this report. GDIT should forward it to Medwatch. If the patient did received an adult RSV (Pfizer or GSK), we do want to track those

Thanks

Pedro

Restricted Use/Recipients Only

---

**From:** Ennulat, Carol (CDC/NCEZID/DHQP/ISO) (CTR) <scq4@cdc.gov>  
**Sent:** Thursday, March 21, 2024 12:23 PM  
**To:** Moro, Pedro (CDC/NCEZID/DHQP/ISO) <psm9@cdc.gov>  
**Cc:** Brown, Hannah (CDC/NCEZID/DHQP/ISO) (CTR) <rw12@cdc.gov>  
**Subject:** VAERS 2742477

Hi Pedro,

The above VAERS is a 1-month old infant who passed on the day of receiving the RSV (Sanofi Pasteur) vaccine.

It was assigned to the adult RSV project so it will be misclassified but I wanted to make you aware.

Please advise if you need us to do anything else.

Best regards,

Carol

Carol W. Ennulat MBA, PA-C (CTR)  
VAERS Project Coordinator/Clinician  
Lukos, LLC  
Division of Healthcare Quality Promotion (DHQP)/Immunization Safety Office (ISO)  
Centers for Disease Control and Prevention  
Phone: (404) 718-3315; Email: [scq4@cdc.gov](mailto:scq4@cdc.gov)